Physician profile
Jiyon Kim
NPI 1942388061
$12,090.16
in general payments reported to CMS, 2019-2025
29 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 91% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,819 · 2022: $2,697 · 2023: $4,185 · 2024: $1,205 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,774 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,250 · Education: $300 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,773.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,250.00 |
| Education | $299.97 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,826.11 | 2021-2024 | Taltz |
| Janssen Biotech, INC. | $1,436.86 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,182.83 | 2021-2025 | |
| Genzyme Corporation | $748.25 | 2021-2025 | |
| Amgen INC. | $652.60 | 2021-2023 | Otezla |
| Regeneron Healthcare Solutions, INC. | $613.64 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $609.06 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $536.60 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $406.82 | 2021-2025 | Absorica Ld, Winlevi |
| Incyte Corporation | $366.14 | 2021-2024 | Opzelura |
| Almirall LLC | $346.68 | 2021-2024 | Klisyri |
| Pfizer INC. | $343.24 | 2021-2025 | |
| Medimetriks Pharmaceuticals, INC. | $250.00 | 2025 | Neo-Synalar, Ketodan |
| Vyne Pharmaceuticals INC. | $242.78 | 2021 | |
| Dermavant Sciences, INC. | $183.85 | 2023-2024 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $175.33 | 2021-2022 | |
| Journey Medical Corporation | $149.28 | 2022 | |
| Genentech USA, INC. | $130.84 | 2021 | |
| Galderma Laboratories, L.P. | $129.53 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $127.43 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $120.75 | 2021 | |
| Ucb, INC. | $119.74 | 2021-2022 | |
| Epi Health, LLC | $107.73 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.50 | 2021-2023 | Arazlo, Jublia |
| Paratek Pharmaceuticals, INC. | $86.65 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $38.71 | 2023-2024 | Ycanth |
| Sandoz INC. | $25.08 | 2023 | Hyrimoz |
| Biofrontera INC. | $19.58 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $9.55 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiyon Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.